IDEXX Laboratories, Inc. $IDXX Shares Sold by Franklin Resources Inc.

by · The Cerbat Gem

Franklin Resources Inc. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 3.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 572,978 shares of the company’s stock after selling 19,671 shares during the quarter. Franklin Resources Inc.’s holdings in IDEXX Laboratories were worth $366,070,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Van ECK Associates Corp boosted its stake in IDEXX Laboratories by 1.0% during the 3rd quarter. Van ECK Associates Corp now owns 24,101 shares of the company’s stock valued at $15,398,000 after acquiring an additional 237 shares during the last quarter. Promus Capital LLC increased its position in shares of IDEXX Laboratories by 1.9% in the 3rd quarter. Promus Capital LLC now owns 2,451 shares of the company’s stock worth $1,566,000 after purchasing an additional 46 shares during the last quarter. Capital Research Global Investors increased its position in shares of IDEXX Laboratories by 0.8% in the 3rd quarter. Capital Research Global Investors now owns 690,601 shares of the company’s stock worth $441,218,000 after purchasing an additional 5,641 shares during the last quarter. Bank of Montreal Can raised its stake in shares of IDEXX Laboratories by 14.9% in the 3rd quarter. Bank of Montreal Can now owns 139,126 shares of the company’s stock valued at $88,886,000 after purchasing an additional 18,025 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of IDEXX Laboratories by 4.1% in the 3rd quarter. Legal & General Group Plc now owns 675,535 shares of the company’s stock valued at $431,593,000 after purchasing an additional 26,909 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.3%

NASDAQ IDXX opened at $600.52 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The company has a 50-day simple moving average of $662.20 and a 200-day simple moving average of $667.66. The firm has a market capitalization of $47.81 billion, a PE ratio of 45.95, a price-to-earnings-growth ratio of 3.64 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the company earned $2.53 EPS. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on IDXX shares. BTIG Research decreased their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Piper Sandler reduced their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Barclays decreased their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

Get Our Latest Research Report on IDXX

Insider Activity at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 2,693 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the sale, the executive vice president directly owned 19,899 shares in the company, valued at approximately $13,163,984.46. This represents a 11.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the sale, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

See Also

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).